Trials / Completed
CompletedNCT04068831
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Conditions
- Metastatic Renal Cell Carcinoma
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talazoparib | 1 mg talazoparib daily |
| DRUG | Avelumab | 800 mg avelumab every 2 weeks |
Timeline
- Start date
- 2019-08-22
- Primary completion
- 2023-12-06
- Completion
- 2023-12-06
- First posted
- 2019-08-28
- Last updated
- 2024-12-27
- Results posted
- 2024-12-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04068831. Inclusion in this directory is not an endorsement.